BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 22, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Viva in vivo! At EHA, in vivo CAR T data continues to impressBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Onko-innate CEO Jai Rautela and CSO NIcholas Huntington
Cancer

Onko-innate seeks targets thought to be undruggable

March 12, 2024
By Tamra Sami
A new spinout from Monash University in Melbourne, Australia, is tackling biology to better understand immune cell function and to find targets that were thought to be undruggable. Onko-innate co-founders Jai Rautela and Nicholas Huntington first worked together at Huntington’s lab at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne where they studied the role of natural killer (NK) cells in tumor immunology and discovered some interesting regulatory pathways for cytokine responses.
Read More

Other news to note for March 12, 2024

March 12, 2024
Additional early-stage research and drug discovery news in brief, from: Athira Pharma.
Read More
Cancer

University of Toronto discovers new HDAC6 inhibitors

March 12, 2024
University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders.
Read More
Cancer

Allist Pharmaceuticals presents new PRMT5 inhibitors for cancer

March 12, 2024
Shanghai Allist Pharmaceuticals Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Suzhou Kintor Pharmaceuticals describes new protein degradation inducers

March 12, 2024
Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders.
Read More
Cancer

Nerviano Medical Sciences divulges new WRN inhibitors

March 12, 2024
Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.
Read More
Neurology/Psychiatric

Japanese researchers patent new inhibitors of TNKS1 and TNKS2

March 12, 2024
Researchers at the Japanese Foundation for Cancer Research and RIKEN have disclosed tankyrase 1 (TNKS1; PARP5A) and/or TNKS2 (PARP5B) inhibitors reported to be useful for the treatment of cancer, metabolic disease, cartilage injury, multiple sclerosis, pulmonary fibrosis, amyotrophic lateral sclerosis, herpes simplex virus and Epstein Barr virus infections.
Read More
Multiple myeloma cells in the bone marrow.
Immuno-oncology

Trispecific antibody SIM-0500 approved for trials in the US and China for multiple myeloma

March 12, 2024
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma.
Read More
Cancer cells
Cancer

Aprea’s WEE1 inhibitor set to enter phase I for cyclin E-overexpressing cancers

March 12, 2024
Aprea Therapeutics Inc. has received FDA clearance of its IND application for APR-1051, a next-generation inhibitor of WEE1 kinase.
Read More
Gene editing illustration
Cancer

Akribion successfully synthesizes constructs combining its G-dase E nuclease with Transcode’s TTX platform

March 12, 2024
Transcode Therapeutics Inc. has reported promising proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics AG.
Read More
Previous 1 2 … 811 812 813 814 815 816 817 818 819 … 18102 18103 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing